The fourth-quarter earnings season is in full swing for the drug and biotech sector.  The performance of the large drugmakers that have reported so far has been rather lukewarm, with most posting mixed results.Higher tax rates due to changes in global tax regulations, concerns around the economy and inflation, regular pipeline setbacks and the slow ramp-up of newer drugs are some concerns of drug developers. Uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s ...